BTK and rheumatoid arthritis: Of the four failed trials reported in RA, branebrutinib, polsetinib, and spebrutinib drug candidates are covalent BTK inhibitors that were tested over periods of 12 weeks, 12 weeks, and 4 weeks, respectively and one was noncovalent (BMS-986142) tested over a 4 week trial period.